

PCT/GB00/03378  
February 27, 2002

### **Clean Copy of Amended Claims**

5. (Amended) A method as claimed in claim 1 wherein between them the sectors flanking the cationic sector have 3 tryptophan residues.
11. (Amended) A method as claimed in claim 1 or 7 wherein the peptide is 12 to 25 amino acids in length.
15. (Amended) A peptide as claimed in claim 12 or 13 having an  $IC_{50}$  non-malignant/tumour cell ratio of greater than 18.
16. (Amended) A peptide produced by the method of claim 1 or 7 .
18. (Amended) A method of treating benign or malignant tumours or preventing or reducing metastasis which comprises administration to a patient in need thereof, of an amount of a peptide produced by the method of claim 1 or 7 or a peptide as claimed in claim 12 or 13 which is sufficient to destroy or reduce the tumour in size or number or prevent or reduce metastasis.
19. (Amended) A pharmaceutical composition comprising a peptide produced by the method of claim 1 or 7 or a peptide as claimed in claim 12 or 13 together with a physiologically acceptable diluent, carrier or excipient.
20. (Amended) A method for the production of a pharmaceutical composition comprising a method of peptide production as claimed in claim 1 or 7 and mixing of the compound prepared thereby or a derivative thereof with a pharmaceutically acceptable carrier.

PCT/GB00/03378  
February 27, 2002

22. A non-peptide biomimetic organic compound which is equivalent to a peptide produced by the method of claim 1 or 7 or a peptide as claimed in claim 12 or 13.